Calamos Advisors
HZNP

Calamos Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Calamos Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-88,000
Closed -$9.48M – 1255
2021
Q4 		$9.48M Buy
+88,000
New +$9.6M 0.04% 511

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Calamos Advisors's HZNP Position: Q4 2023 in Review

Calamos Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 100,000 shares — an estimated $11.6M sold.

Calamos Advisors first reported a position in HZNP in Q4 2018 and held it in 16 quarters. The position peaked at $24.9M in Q1 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Calamos Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Calamos Advisors sold 100,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $11.6M.
  • Calamos Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2018 and held it in 16 quarters.
  • Calamos Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $24.9M in Q1 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Calamos Advisors's 13F filing for Q4 2023, filed 31 Jan 2024.